Long-Term Management and Monitoring in IBD

In this episode, “Long-Term Management and Monitoring in IBD,” our panel explores the importance of ongoing disease management, treatment adherence, and long-term monitoring in patients living with inflammatory bowel disease (IBD). The patient panelist discusses experiences with gaining timely access to biologic therapy, including coordination with the medical team, insurance approval, and the importance of continued communication throughout treatment. The panel also highlights how achieving symptom relief and favorable colonoscopy findings reinforced confidence in continuing therapy and maintaining close follow-up care.

Throughout the discussion, expert faculty emphasize that IBD is a chronic condition requiring long-term treatment and monitoring, even when patients begin feeling well or achieve remission. The panel reviews the importance of maintaining biologic therapy to reduce the risk of disease recurrence and discusses how disease activity can return or evolve when treatment is discontinued. Expert faculty also explain how clinicians monitor treatment response over time using objective measures such as fecal calprotectin, laboratory testing, symptom assessment, and endoscopic evaluation to guide long-term management decisions.

In addition, the conversation explores the importance of patient advocacy, adherence to follow-up appointments, and collaboration with the healthcare team to optimize long-term outcomes. Expert faculty discuss how delayed response to therapy can occur in some patients and explain how treatment decisions are individualized based on symptom improvement and objective evidence of disease control. The panel concludes by reinforcing the importance of persistence, monitoring, and personalized care in achieving sustained remission and quality of life in IBD.

Our next episode, “Addressing Safety Concerns with Biologic Therapies in IBD,” highlights how panelists approach patient concerns surrounding biologic therapy safety, long-term monitoring, and individualized treatment selection in IBD. The panel also discusses the importance of preventive care, multidisciplinary management, and improving quality of life through optimized disease control.